NCT02707159View on ClinicalTrials.gov

Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

January 31, 2019

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

Nab paclitaxel / gemcitabine

Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy

Trial Locations (1)

4068

Stavanger University Hospital, Stavanger

All Listed Sponsors
lead

Helse Stavanger HF

OTHER_GOV

NCT02707159 - Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter